Eli Lilly (LLY) and Walmart (WMT) announced a partnership to expand access to Zepbound (tirzepatide) through LillyDirect’s direct-to-consumer healthcare platform.
Starting mid-November, Zepbound single-dose vials will be available for pickup at Walmart pharmacies nationwide. All approved strengths will be available, with the lowest dose starting at $349 per month.
Patients with a valid prescription can buy Zepbound directly, without using insurance, gaining more convenient access through Walmart’s pharmacy network.
“The strategic collaboration marks the first time patients using LillyDirect, Lilly’s direct-to-consumer healthcare platform, can access self-pay pricing for Zepbound vials at a retail pharmacy location,” said in a statement.
